← Back to Search

Pentraxin

PRM-151 for Idiopathic Pulmonary Fibrosis (STARSCAPE Trial)

Phase 3
Waitlist Available
Research Sponsored by Hoffmann-La Roche
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline up to 2.5 years
Awards & highlights

STARSCAPE Trial Summary

This trial will compare the effects of a new drug, PRM-151, to placebo in people with IPF. The study will measure how well the drug works, how safe it is, and how it is metabolized.

Eligible Conditions
  • Idiopathic Pulmonary Fibrosis

STARSCAPE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline up to 2.5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline up to 2.5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Absolute Change in Forced Vital Capacity (FVC [mL])
Secondary outcome measures
Absolute Change in 6-minute Walk Distance (6MWD)
Absolute Change in FVC% Predicted
Change from Baseline in Targeted Clinical Laboratory Test Results
+13 more

STARSCAPE Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: PRM-151Experimental Treatment1 Intervention
Participants will receive intravenous (IV) infusions of PRM-151 over 50-70 minutes on Days 1, 3 and 5, then followed by infusions every 4 weeks (Q4W) to Week 48.
Group II: PlaceboPlacebo Group1 Intervention
Participants will receive IV infusions of placebo over 50-70 minutes on Days 1, 3 and 5, followed by infusions Q4W to Week 48.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PRM-151 (Zinpentraxin Alfa)
2021
Completed Phase 3
~670

Find a Location

Who is running the clinical trial?

Hoffmann-La RocheLead Sponsor
2,428 Previous Clinical Trials
1,088,389 Total Patients Enrolled
16 Trials studying Idiopathic Pulmonary Fibrosis
3,894 Patients Enrolled for Idiopathic Pulmonary Fibrosis
Clinical TrialsStudy DirectorHoffmann-La Roche
2,199 Previous Clinical Trials
887,837 Total Patients Enrolled
16 Trials studying Idiopathic Pulmonary Fibrosis
4,129 Patients Enrolled for Idiopathic Pulmonary Fibrosis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are adults the only ones who can sign up for this experiment?

"This clinical trial has an age limit of 40-85 years old."

Answered by AI

Is this the first set of tests for PRM-151?

"PRM-151 was first researched in 2021 at Hospital Universitario Fundacion Jimenez Diaz. Since the initial study, there have been 18268 more completed studies. Out of the current 2 live studies, a considerable amount are based in Hamilton, Ontario."

Answered by AI

Has this particular type of research been conducted before?

"As of right now, there are 2 ongoing studies for PRM-151 in 161 cities and 38 countries. The first trial for PRM-151 occurred in 2021. The 658 participants completed Phase 3 drug approval and the study was sponsored by Hoffmann-La Roche. In the years since 2021, 18268 more studies have taken place."

Answered by AI

Are there several sites in the city where this clinical trial is taking place?

"There are 103 total clinical trial sites for this experiment, which are based in St. Joseph's Healthcare Hamilton (Canada), Metroplex Pulmonology & Sleep Center (USA), University of Cincinnati Cancer Institute (USA), and 100 other locations."

Answered by AI

Who else is applying?

What state do they live in?
New Jersey
Michigan
How old are they?
65+
What site did they apply to?
University of Chicago Medical Center
Newark Beth Israel Medical Center
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
2021. "A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04552899.
~163 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top